Breaking Finance News

Redx Pharma Plc (LON:REDX) target price held steady at 105.00GBX, reported today by Cantor Fitzgerald

Having a price of 36.00GBX, Redx Pharma Plc (LON:REDX) traded 8.25% higher on the day. The last stock price close is up 9.72% relative to the two hundred day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the date range. REDX has logged a 50-day average of 27.20GBX and 200-day moving average of 32.06GBX. 308,583 shares of REDX traded, up from ann avg. trading volume of 109,027

Cantor Fitzgerald held the target stock price of Redx Pharma Plc (LON:REDX) at 105GBX, stating a possible upside of 1.92%,

On 9/06/2016, Cantor Fitzgerald released a statement for Redx Pharma Plc(LON:REDX) kept the target price at 105.00GBX. At the time, this indicated a possible upside of 2.96%.

Recent Performance Graph:

Redx Pharma Plc (LON:REDX)

With a market capitalization of 0.0 GBX, Redx Pharma Plc has a 52 week low of 23.00GBX and a 52 week high of 105.00GBX with a PE ratio of 0.

General Company Details For Redx Pharma Plc (LON:REDX)

Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton’s Tyrosine Kinase (BTK), which has reached candidate nomination stage. The Company’s oncology research activity also include Porcupine program, Colony Stimulating Factor-1 receptor (CSF-1) program, Indoleamine-pyrrole 2, 3-dioxygenase (IDO) inhibitor and Pan-Raf inhibitor. The Company’s anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX003, and is a class of antibiotic acting through the type II bacterial topoisomerases. It is also evaluating BTK inhibitor for immunological disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *